within Pharmacolibrary.Drugs.N_NervousSystem.N07A_Parasympathomimetics.N07AB02_Bethanechol;

model Bethanechol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.1,
    Cl = 1.6666666666666667e-06,
    adminDuration = 600,
    adminMass = 25 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bethanechol</td></tr><tr><td>ATC code:</td><td>N07AB02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>25</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bethanechol is a synthetic choline ester and a parasympathomimetic agent that selectively stimulates muscarinic receptors without effect on nicotinic receptors. It is primarily used to treat urinary retention by stimulating contraction of the bladder muscle and for certain gastrointestinal disorders like postoperative ileus. It is an older drug and still approved in several countries for specific indications.</p><h4>Pharmacokinetics</h4><p>No well-characterized clinical pharmacokinetic studies available in humans; PK parameters are estimated based on limited animal data and drug class behavior.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N07AB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bethanechol;
